Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study - Wikidata - awgldk - TriplyDB

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

http://www.wikidata.org/entity/Q28202724

about

sameAs

Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines EpCAM (CD326) finding its role in cancer The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patients Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer 'Trial Exegesis': Methods for Synthesizing Clinical and Patient Reported Outcome (PRO) Data in Trials to Inform Clinical Practice. A Systematic Review Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.Overview of the clinical efficacy of investigational anticancer drugs.Recent advances in the pharmacological treatment of colorectal cancer.Adjuvant therapy for colon cancer in the new millenium.Recent randomised trials in colorectal disease.Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581 Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro.Using antibodies in tumour immunotherapy.Targeted therapies for cancer 2004.Chemoradiotherapy for colorectal cancer An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer.Review article: immune suppression and colorectal cancer.Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges.Current role of antibody therapy in patients with metastatic colorectal cancer.Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.Reduction in membranous immunohistochemical staining for the intracellular domain of epithelial cell adhesion molecule correlates with poor patient outcome in primary colorectal adenocarcinoma Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.Progress and challenges in the adjuvant treatment of stage II and III colon cancers.Adjuvant therapy of colon cancer: current status and future developments Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?Monoclonal antibodies used as prophylactic, therapeutic and diagnostic agents.Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins.Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool.Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors.Monoclonal antibodies in gastrointestinal cancers.Antibody-based therapy in colorectal cancer.Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness.Trop2: from development to disease.

P2860

Q24650717-486C82AF-4835-401C-A061-05493C2E5EAB Q24653692-60BB85D7-6BE9-48ED-9D27-A1156A6180D8 Q26738665-3204E7F3-EB03-4659-B4F4-67B29E9A271C Q27024651-DFA51DC5-664C-4755-A0E6-E65293D72E1D Q28077999-868CE4CE-540B-46A2-A0F5-12D09B78DA16 Q28235980-89CC8368-B4F0-47D2-8281-77094E3DED03 Q31125157-CA0D2269-6811-43A6-B488-D2722EAE0AAA Q33247794-1DA27590-C9ED-4491-9863-4ACB53F861D0 Q34434814-092A8E8F-43F8-42A8-8273-3147FCB89084 Q35067125-C3F0561F-0E56-4FFD-A870-6CF8D1A3E540 Q35073360-975ED4FC-13EB-46AB-81A3-87E09EDC5169 Q35111174-C37DB9E3-D636-4080-8932-EBAD6B85AFF0 Q35157518-39E5A9B4-050C-4901-9ECB-90ECF024A8AD Q35170266-5EA37CD0-15A8-475D-B66E-B5A241AC9722 Q35623575-C9527101-A5E4-4AD1-B821-9BB0DC45FA5E Q35842612-EBD5DE1A-957D-4214-ABB1-45EC7EC99DEC Q35919642-8D5784A0-A631-4744-9385-495462B36EE0 Q36189950-01FD16A0-5CA1-4302-889F-E7B0CA3A354B Q36413078-4DF01BEA-40CC-4A5F-BECE-3080D6016B73 Q36413103-2EECADF3-E47A-4744-ABE7-2E5D8BA9DEBF Q36529848-04EBB142-A239-4F2E-9900-98A0D6DCF666 Q36609898-E089CF81-F46C-4A0E-B2D0-C3F9F9EC621F Q36613499-33279F91-5210-4102-95FC-061B4BCD029F Q36746340-4575E589-2383-4748-93C6-8BE3772123C6 Q36832121-A327C882-A866-4A80-B9E1-6F440FB34893 Q36862977-316AC559-6257-44CC-9D5C-9FFCEB797840 Q36989107-667807E8-D450-4977-96D2-F021D1496E2F Q37134430-718ECC1F-CCEC-4448-9D24-A974D3EF4255 Q37134442-D3D8A6A0-FA56-4F8A-B274-B6E8F85EEF7C Q37427518-ED73F4A4-57C8-4BF8-BE30-8E2F93FB7BC7 Q37666618-E418F2B6-AD70-41EA-8858-726F03406418 Q37701457-0F2F31F5-9EE9-4636-915F-E5A31DDF651E Q37725990-A63ABD74-C141-4690-965C-56921A621564 Q37738903-E9C56E78-106D-498D-861D-6458981AD1BF Q37860943-88F0FB2B-83A8-44B4-82BF-4B9FB808CFB0 Q37887819-A40B2B0A-6CBC-4BCA-B4CC-127927EB72A1 Q38084684-54390423-F0C7-42B4-8D6E-DC65A9E7E6B6 Q38103583-07A8A505-9A43-470E-BCFB-91DE8CBFE28D Q38249339-E4ED8A49-1957-4E34-AF13-2B98B1C816CB Q38293559-9813B0F0-3455-48FC-9535-6916C5261251

P2860

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

http://www.wikidata.org/entity/Q28202724

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Edrecolomab alone or in combin ...... lon cancer: a randomised study

@ast

Edrecolomab alone or in combin ...... lon cancer: a randomised study

@en

Edrecolomab alone or in combin ...... lon cancer: a randomised study

@nl

type

label

Edrecolomab alone or in combin ...... lon cancer: a randomised study

@ast

Edrecolomab alone or in combin ...... lon cancer: a randomised study

@en

Edrecolomab alone or in combin ...... lon cancer: a randomised study

@nl

prefLabel

Edrecolomab alone or in combin ...... lon cancer: a randomised study

@ast

Edrecolomab alone or in combin ...... lon cancer: a randomised study

@en

Edrecolomab alone or in combin ...... lon cancer: a randomised study

@nl

P1433

Q28202724-C559E460-064C-4D68-A6FE-D90C0379DF4D

P1476

Q28202724-CB927503-E443-40A2-B945-307E8EC0B111

P2093

Q28202724-017F574A-4242-4315-946B-A72981952884

Q28202724-0D915DCA-FA71-462A-8AF0-4523A609F552

Q28202724-0E6C79F9-9D12-4FF3-B00D-B407C322CAF3

Q28202724-3D049C1E-D8D8-4453-992F-D6A5AE67A1CB

Q28202724-49172934-014C-45C3-B998-22817AD4F83E

Q28202724-859AAA9A-6A01-4F0B-9E3F-59954D89DFDC

Q28202724-9106A3ED-E492-4173-8DB6-C1A446BF5986

Q28202724-933BE988-169E-487D-88FE-7F698A2E7FA5

Q28202724-95348888-720C-4DDC-8379-DA5E1743A9B1

Q28202724-CEAC38E0-3F22-4AEF-82C0-732E035FAEBB

P304

Q28202724-36F2EAF3-128B-4A70-9AA7-4AA3931951D6

P31

Q28202724-6913D7EC-EE58-418B-B889-1368B6F70142

P3181

Q28202724-9812BFDF-85F9-4147-807C-D63578C9181D

P356

Q28202724-B5D9DF6F-7C54-4778-BF10-C6367E894FB1

P407

Q28202724-54F06F34-6641-459F-B4E2-3EB24B40EACE

P433

Q28202724-DD2B1284-DF89-44DE-B0FC-01F5E03DB0E8

P478

Q28202724-2CC16C72-3917-41E1-B144-B1B994CD6B3D

P50

Q28202724-D5D9E5A6-0862-405D-A5C8-EDCCA44A2B3E

P577

Q28202724-FC7F53DB-8A12-48A4-B018-C0D759005991

P698

Q28202724-B28F0670-2AE9-43B9-99F9-F60A5A2D598A

P3181

P356

S0140-6736(02)09836-7

P1433

P1476

Edrecolomab alone or in combin ...... lon cancer: a randomised study

@en

P2093

Arie Figer

http://www.w3.org/2001/XMLSchema#string

Attila Nagy

http://www.w3.org/2001/XMLSchema#string

Carlo Barone

http://www.w3.org/2001/XMLSchema#string

Cornelis J A Punt

http://www.w3.org/2001/XMLSchema#string

Delyth Jones

http://www.w3.org/2001/XMLSchema#string

Eugene Moylan

http://www.w3.org/2001/XMLSchema#string

George Fountzilas

http://www.w3.org/2001/XMLSchema#string

Hanno Riess

http://www.w3.org/2001/XMLSchema#string

Jessica Colman

http://www.w3.org/2001/XMLSchema#string

John Monson

http://www.w3.org/2001/XMLSchema#string

P304

671-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3316503

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(02)09836-7

http://www.w3.org/2001/XMLSchema#string

P407

P433

9334

http://www.w3.org/2001/XMLSchema#string

P478

360

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Yves Douillard

P577

2002-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12241873

http://www.w3.org/2001/XMLSchema#string